Within 30days post-treatment , seven chronic obstructive pulmonary disease exacerbations ( 6.1 % ) , six pneumonias ( 5.2 % ) , four pneumothoraces ( 3.5 % ) and one haemoptysis ( 0.9 % ) occurred as serious adverse events .